Advancements in biologics, personalized medicine, and rising global prevalence drive the psoriasis treatment market's exponential growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment ...

The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

A new decade brings new skin concerns. “Aging seems to appear rather dramatically and suddenly in your 40s due to the onset of hormonal changes,” says Dr. Zenovia Gabriel, a Newport Beach ...

Losing weight after 40 can feel like an uphill battle, with factors like slower metabolism, hormonal changes, and decreased muscle mass making it more challenging than ever. Understanding these ...

TVs seem to be getting bigger and bigger every year, but sets that measure 40 inches across the diagonal are a good choice for those looking for a mid-size television that provides a balance ...

AbbVie held onto almost all of the Humira market for more than a year after close copies of the drug were launched in early 2023. That changed when CVS Health (NYSE:CVS) removed Humira from its ...

First, I will answer the first question. The answer to this question lies in the sharp drop in Humira sales due to the negative impact of its biosimilars and AbbVie's effort to switch patients ...

For the unversed, traditionally 40-hour workweek is established as the standard working hours in many countries. While modern work culture has evolved to accommodate various work schedules-- from ...

Amjevita contains the active ingredient adalimumab-atto and is a biosimilar of the brand-name drug Humira (adalimumab). The “-atto” appears at the end of Amjevita’s name to show it’s ...

There are life skills that people need to have as they get older. Here are 15 of them that should be mastered before you turned 40. It’s been said that public speaking is the average person’s number ...

Additionally, specialty growth is said to be accelerating, with Cordavis penetration increasing and over 90% of Humira patients now using biosimilars. Despite the upbeat outlook, Leerink Partners ...